Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05252416
Title (VELA) Study of BLU-222 in Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Blueprint Medicines Corporation

Advanced Solid Tumor

ovarian cancer

Her2-receptor negative breast cancer

endometrial cancer

stomach cancer


BLU-222 + Carboplatin

BLU-222 + Fulvestrant + Ribociclib

BLU-222 + Fulvestrant

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.